19 Oct. (Fri.);
Annual Meeting of Korean Society for Transplantation (KST)
20 Oct. (Sat.);
Korea-Japan Transplantation Forum 2012 (AM)
Annual Meeting of Korean Society for Transplantation (KST)(PM)
08:30~08:40 |
°³È¸»ç |
¼º¸¾ç (¿µ³²ÀÇ´ë) |
08:40~09:40 |
Grants Presentation(¿¬±¸ºñ)
ÁÂÀå : ¼º¸¾ç (¿µ³²ÀÇ´ë) Á¶¹éȯ (ÀüºÏÀÇ´ë) |
08:40~08:55 |
Immunologic Monitoring of T-lymphocyte Subsets and HLA-DR Positive
Monocyte in Kidney Transplant Recipients
|
±èÂù´ö(°æºÏÀÇ´ë) |
08:55~09:10 |
Analysis of S Gene Mutation of Hepatitis B Virus in Adult Liver Transplant
Recipients showing Resistance to Prophylactic Therapy Using High-dose
Hepatitis B Immunoglulin
|
¹®´öº¹(¿ï»êÀÇ´ë) |
09:10~09:25 |
Effect of CXCR3 Polymorphisms on Graft Outcomes in Kidney Transplantation |
Çã±ÔÇÏ(¿¬¼¼ÀÇ´ë) |
09:25~09:40 |
³ú»çÀå±â±âÁõ È°¼ºÈ¸¦ À§ÇÑ ÀÇ·áÀÎ ±³À° ±³Àç ¹ß°£ |
¹Î»óÀÏ(¼¿ïÀÇ´ë) |
09:40~10:30 |
Plenary Lecture
ÁÂÀå : ÀÌ½Â±Ô (¿ï»êÀÇ´ë), ¹®Àμº (°¡Å縯ÀÇ´ë)
Use of ECMO for uncontrolled (Maastricht classification I) DCD donors
Shawn J. Pelletier (University of Michigan Health Systems) |
10:30~11:00 |
Coffee Break |
11:00~12:00 |
Concurrent Symposium I :
Kidney Transplantation Concurrent Session
Antibodies and B cells in kidney transplantation
ÁÂÀå : ÇÑ´öÁ¾ (¿ï»êÀÇ´ë) ¹Ú¸íÈñ (¼¿ïÀÇ´ë) |
11:00~11:20 |
Role of B cell in allograft injury and clinical tolerance |
ÀÌÁ¾¼ö(¿ï»êÀÇ´ë) |
11:20~11:40 |
Update in treatment of acute and chronic antibody mediated rejection |
¹Ú°üÅÂ(°í·ÁÀÇ´ë) |
11:40~12:00 |
Antibody to Minor HLA antigens in acute and chronic allograft rejection |
¼ÛÀº¿µ(¼¿ïÀÇ´ë) |
11:00~12:00 |
Concurrent Symposium II :
Liver Transplantation Concurrent Session
Liver Transplantation in Hepatitis C
ÁÂÀå : À̼®±¸ (¼º±Õ°üÀÇ´ë) ±è¼øÀÏ (¿¬¼¼ÀÇ´ë) |
11:00~11:20 |
°£ÀÌ½Ä ¼ö¼ú Àü C Çü °£¿°ÀÇ °ü¸® ¹× Ç×¹ÙÀÌ·¯½º ¾àÁ¦ÀÇ ¼±Åà |
¹è½ÃÇö(°¡Å縯ÀÇ´ë) |
11:20~11:40 |
Management and immunosuppression for HCV after Liver Transplantation |
À̱¤¿õ(¼¿ïÀÇ´ë) |
11:40~12:00 |
Liver transplantation and retransplantation for patients with hepatitis C virus-
associated diseases and hepatocellular carcinoma
|
Ȳ ½Å(¿ï»êÀÇ´ë) |
11:00~12:00 |
Concurrent Symposium III :
Pathology Concurrent Session
ÁÂÀå : 䵿¿Ï (¼¿ïÀÇ´ë) Á¤ÇöÁÖ (¿¬¼¼ÀÇ´ë) |
11:00~11:15 |
Introduction of renal transplantation pathology |
±è¿ëÁø(¿µ³²ÀÇ´ë) |
11:15~11:30 |
Pathologic updates on Antibody Mediated Rejection |
ÃÖ¿µÁø(°¡Å縯ÀÇ´ë) |
11:30~11:45 |
T-cell-mediated rejection with an emphasis on acute vascular rejection |
Á¶¿µ¹Ì(¿ï»êÀÇ´ë) |
11:45~12:00 |
Non-immunologic allograft failure |
¹®°æö(¼¿ïÀÇ´ë) |
12:00~12:30 |
Á¤±âÃÑȸ |
12:30~13:30 |
Luncheon Symposium I,II(Á¾±Ù´ç, ·Î½´) |
13:30~14:45 |
ÀÚÀ¯¿¬Á¦ 1 : Kidney ÁÂÀå : ÀÌ»ï¿ (ÇѸ²ÀÇ´ë) ±è¿µÈÆ (ÀÎÁ¦ÀÇ´ë) |
13:30~13:42 |
Determination of rituximab dose according to immunologic risk in ABO
incompatible KT |
¾È°ÇÈñ(°¡Å縯ÀÇ´ë) |
13:42~13:54 |
ABO-incompatible living-donor kidney transplantation using low-dose tacrolimus |
Çã±ÔÇÏ(¿¬¼¼ÀÇ´ë) |
13:55~14:07 |
Single center experience of ABO incompatible kidney transplantation |
±è¿µÈÆ(¿ï»êÀÇ´ë) |
14:07~14:19 |
Significance of isoagglutinin titer in ABO-incompatible kidney transplantation |
±Ç¼®¿î(¿ï»êÀÇ´ë) |
14:20~14:32 |
Single center experience of flowcytometry crossmatch positive kidney
Transplantation |
±è¿µÈÆ(¿ï»êÀÇ´ë) |
14:32~14:44 |
Antibody-Mediated Rejection In Pediatric kidney Allograft Recipients; A Risk Factor
Analysis |
ÀÌÁö¿ø(¼¿ïÀÇ´ë) |
13:30~14:45 |
ÀÚÀ¯¿¬Á¦ 2 : Liver ÁÂÀå : ä±Ç¹¬ (¿ø±¤ÀÇ´ë) ÃÖÁø¼· (¿¬¼¼ÀÇ´ë) |
13:30~13:42 |
The 'ABO cross-transplant problem' in liver transplantation |
¹Ú¹Î¼ö(¼¿ïÀÇ´ë) |
13:42~13:54 |
Short-term Outcome of ABO-incompatible Adult Living Donor Liver Transplantation |
±èÁ¾¸¸(¼º±Õ°üÀÇ´ë) |
13:55~14:07 |
Renal function-based determination of mycophenolate dose for monotherapy in
stable liver recipients |
¹Ú¿äÇÑ(¿ï»êÀÇ´ë) |
14:07~14:19 |
Use of generic mycophenolate for conversion maintenance therapy in stable liver
Recipients |
Ȳ ½Å(¿ï»êÀÇ´ë) |
14:20~14:32 |
Outcome of Liver Retransplantation: Analysis of a 24-Year Experience in a Single
Center |
±èÇý¿µ(¼¿ïÀÇ´ë) |
14:32~14:44 |
Familial heterozygous living donor liver transplantation |
ÃÖ¿µ·Ï(¼¿ïÀÇ´ë) |
13:30~14:45 |
ÀÚÀ¯¿¬Á¦ 3 : Basic and Kidney ÁÂÀå : ±èº´Ã¢ (¸Þ¸®³îº´¿ø) ±è¿¬¼ö(¼¿ïÀÇ´ë) |
13:30~13:45 |
Protective effect of Korean red ginseng on chronic cyclosporine-induced renal and
pancreatic injury |
ÀÓ¼±¿ì(°¡Å縯ÀÇ´ë) |
13:45~14:00 |
Intrarenal activation of IL-7 in acute rejection after kidney transplantation |
ÀÌ»óÈ£(°æÈñÀÇ´ë) |
14:00~14:15 |
Comparison of QuantiFERON-TB Gold with Tuberculin Skin Test for Detecting Latent
Tuberculosis Infection before Kidney Transplantation |
±èÁؼ·(°æºÏÀÇ´ë) |
14:15~14:30 |
Effects of Vitamin D and Bisphosphonate on Bone Mineral Density in Kidney
Transplant Recipients |
ÀüÇýÁß(¼¿ïÀÇ´ë) |
14:30~14:45 |
Contrast Enhanced MR angiography and MR imaging in the Early Period After
Kideny transplantation |
±èÁöÀÏ(°¡Å縯ÀÇ´ë) |
14:45~15:00 |
Coffee Break |
15:00~16:15 |
ÀÚÀ¯¿¬Á¦ 4 : Kidney ÁÂÀå : Çã±æ (ºÀ»ýº´¿ø) ±è¼ºÈ¯ (Á¶¼±ÀÇ´ë) |
15:00~15:12 |
Clinical Significance of protocol biopsy at three months after Kidney transplantation |
È«À¯¾Æ(°¡Å縯ÀÇ´ë) |
15:12~15:24 |
The Impact of Time-zero Biopsy in Living Donor Kidney Transplantation for Early
Graft Outcomes |
À̾ƶõ(¿¬¼¼ÀÇ´ë) |
15:25~15:37 |
Significant of Time-zero Biopsy in Deceased Donor Kidney Transplant |
À̾ƶõ(¿¬¼¼ÀÇ´ë) |
15:37~15:49 |
Effects of Switching from Prograf¢ç to Advagraf¢ç in Stable Pediatric Kidney
Transplant Recipient |
¹Î»óÀÏ(¼¿ïÀÇ´ë) |
15:50~16:02 |
Therapeutic Equivalence of Generic Tacrolimus Formulation in De Novo Kidney
Transplant recipients |
¹Î»óÀÏ(¼¿ïÀÇ´ë) |
16:02~16:14 |
Long-term outcome of mycophenolate mofetil versus azathioprine in a cyclosporine-
based immunosuppression in kidney transplant: 10 years experience at single center |
±Ç¿À¾ð(°æºÏÀÇ´ë) |
15:00~16:15 |
ÀÚÀ¯¿¬Á¦ 5 : Liver ÁÂÀå : ÃÖµ¿¶ô (´ë±¸°¡Å縯ÀÇ´ë) ÃÖ¹®¼® (¼º±Õ°üÀÇ´ë) |
15:00~15:12 |
Analysis of Predictive Value of MELD Score for Patient Survival in LDLT |
ÁÖµ¿Áø(¿¬¼¼ÀÇ´ë) |
15:12~15:24 |
Comparison of KONOS Status with MELD score |
À̼öÇü(¿¬¼¼ÀÇ´ë) |
15:25~15:37 |
The Uneven Distribution of Fat in the liver |
ÃÖ¿µ·Ï(¼¿ïÀÇ´ë) |
15:37~15:49 |
»ýü°£ÀÌ½Ä ±âÁõÀÚ·Î µî·ÏÇÑ ±âÁõ¿¹Á¤ÀÚÀÇ °æ°ú¿¡ °üÇÑ °íÂû |
±è¿Á°æ(¼¿ïÀÇ´ë) |
15:50~16:02 |
Prophyaxis and preemptive therapy for CMV infection after liver transplantation in
CMV endemic area |
Áö¿õ¹è(°í·ÁÀÇ´ë) |
16:02~16:14 |
Strategies to reduce infectious complications using epidemiologic data analysis in
liver transplant recipients |
±è»óÀÏ(°¡Å縯ÀÇ´ë) |
15:00~16:15 |
ÀÚÀ¯¿¬Á¦ 6 : Heart, Lung, Organ Donation ÁÂÀå : ¹éȿä (¿¬¼¼ÀÇ´ë) ±èÀçÁß (¿ï»êÀÇ´ë) |
15:00~15:15 |
ÆóÀ̽Ŀ¡¼ ü¿Ü Æó °ü·ù ¸ðµ¨ÀÇ Àû¿ë |
ÇÔ¼®Áø(¿¬¼¼ÀÇ´ë) |
15:15~15:30 |
The efficacy of everolimus to prevent cardiac allograft vasculopathy in patients with
heart transplantation; comparison with cyclosporine-based and tacrolimus-based
protocols |
±èÀçÁß(¿ï»êÀÇ´ë) |
15:30~15:45 |
¼Ò¾Æ¿¬·É¿¡¼ÀÇ ½ÉÀåÀ̽ļö¼ú |
¹ÚÇѱâ(¿¬¼¼ÀÇ´ë) |
15:45~16:00 |
º¹ºÎ ´ÙÀå±â ÀÌ½Ä – ±¹³» ÃÖÃÊ º¸°í |
±è´ë¿¬(¿ï»êÀÇ´ë) |
16:00~16:15 |
Evaluation of the KONOS expanded donor criteria in deceased donor renal
Transplantation |
¹ÚÀÇÁØ(°è¸íÀÇ´ë) |
16:15~16:30 |
Coffee Break |
16:30~17:30 |
Satellite Symposium :
ABO incompatible KT consensus meeting
ÁÂÀå : ±èÀ¯¼± (¿¬¼¼ÀÇ´ë) ¹Ú¼ö±æ (¿ï»êÀÇ´ë) |
16:30~16:45 |
Çѱ¹ÀÇ ABO ºÎÀûÇÕ »ýü ½ÅÀåÀ̽Ä(ABOi KT) |
°øÁø¹Î (BHSÇѼº´¿ø) |
16:45~17:00 |
Adult ABO Incompatible Living Donor Liver Transplantation in Korea |
¿ÕÈñÁ¤ (¾ÆÁÖÀÇ´ë) |
17:00~17:15 |
Ç÷¾×Çü ºÒÀÏÄ¡ ½ÅÀå ÀÌ½Ä °ü·Ã ÃÖ±Ù À̽´ |
¾çö¿ì(°¡Å縯ÀÇ´ë) |
17:15~17:30 |
Panel Discussion |
17:30~18:30 |
Cocktail party |
18:30~ |
Dinner Symposium and Welcome Reception (Astellas) |
07:50~08:00 |
Opening remarks |
Won Hyun Cho (Keimyung Univ.) |
08:00~09:20 |
KJTF 2012 Plenary session :
Strategy for increasing transplant activity
Moderator : Yonson Ku(Kobe Univ.), Won Hyun Cho (Keimyung Univ.) |
08:00~08:20 |
Obstacles of successful donation after cardiac death-Japanese side
|
Kazuhide Saito (Niigata Univ.) |
08:20~08:40 |
Progresses and challenges in improving organ donation-Korean side |
Jong Won Ha (Seoul Univ) |
08:40~09:00 |
Expansion of donor sources. Hurdles of xenotransplantation |
Takaaki Kobayashi (Nagoya Univ) |
09:00~09:20 |
Exchange donor program vs. ABO incompatible transplantation |
Myoung Soo Kim (Yonsei Univ) |
09:20~09:40 |
Coffee Break |
09:40~11:00 |
Free paper 1 : Kidney Moderator : Kazunari Tanabe(Tokyo Women's Medical Univ.), Oh Jung Kwon (Hanyang Univ) |
09:40~09:51 |
Clinical Impact of Pretransplant HLA-DQ Donor-Specific Antibodies in
Kidney Transplantation |
Sang-Il Min(Seoul National Univ.) |
09:51~10:02 |
The clinical study of immunosuppression protocol in ABO-incompatible
kidney transplantation |
Masahiro Ikeda(Niigata Univ.) |
10:02~10:13 |
Efficacy of Early Steroid Withdrawal with Anti-Thymocyte Globulin Induction |
Young Hoon Kim(Ulsan Univ.) |
10:14~10:25 |
Excellent results of both T and B cell FCXM positive cases in living donor
kidney transplantation. |
Soshi Terasaka(Sciences Kyushu Univ.) |
10:25~10:36 |
Decreased Klotho expression is associated with persistent hyperparathyroidism
after KT |
Yu ah Hong(The Catholic Univ.) |
10:36~10:47 |
Beneficial Effects of Tonsillectomy in Kidney Transplant Patients with
Recurrent IgA Nephropathy |
Naotsugu Ichimaru(Osaka Univ.) |
10:48~10:59 |
Change of risk factors affecting renal allograft survival by transplant era |
Lee A-Lan(Yonsei Univ.) |
09:40~11:00 |
Free paper 2 : Liver Moderator : Susumu Eguchi(Nagasaki Univ.), Kyung-Suk Suh (Seoul Univ.) |
09:40~09:51 |
Usefulness of alpha-fetoprotein and C-reactive protein as preoperative markers of
prognosis in patients with hepatocellular carcinoma after living donor liver
transplantation |
Shozo Mori(Dokkyo Medical Univ.) |
09:51~10:02 |
Tumor pathology at the time of primary liver resection is associated with recurrence
of hepatocellular carcinoma after salvage liver transplantation: a multicenter analysis
of 82 cases |
Sanghoon Lee(Sungkyunkwan Univ.) |
10:02~10:13 |
The outcomes of patients with severe hyperbilirubinemia following living donor
liver transplantation |
Hajime Matsushima(Nagasaki Univ.) |
10:14~10:25 |
Outcome of various treatments for post-transplant hepatitis B virus
Recurrence |
Nam-Joon Yi (Seoul National Univ.) |
10:25~10:36 |
Peripheral blood marker for acute cellular rejection in liver transplantation. |
Naoki Hama(Osaka Univ.) |
10:36~10:47 |
S gene mutation of hepatitis B virus in liver transplant recipients showing HBIG
Resistance |
Gil-Chun Park(Ulsan Univ.) |
10:48~10:59 |
Fragility Index, A Novel Predictor to Assess CKD after Living Donor Liver
Transplantation |
Kaori Kuramitsu(Kobe Univ.) |
09:40~11:00 |
Free paper 3 : Basic and Other Moderator : Takashi Kenmochi(Fujita Health Univ.), Chul Woo Yang (Catholic Univ.) |
09:40~09:51 |
Multi-photon microscopy-based kidney live imaging in a rat acute kidney rejection
Model |
Junya Kaimori(Osaka Univ.) |
09:51~10:02 |
Islet allograft rejection in sensitized mice is refractory to combination of immune-
modulating agent |
Tai Yeon Koo(Seoul National Univ.) |
10:02~10:13 |
The Effect of Adipose Derived Mesenchymal Stem Cell for the Tolerance and Treg
Role in vitro Study |
Jong won HONG(Yonsei Univ.) |
10:14~10:25 |
Impact of the flowcytemetric crossmatch B-cell positive in living renal transplantation |
Kei Kurihara(Hidehisa Kitada) |
10:25~10:36 |
False-positive T-NIH cytotoxicity test results due to autoantibodies in KONOS
crossmatch tests |
Hyewon Park(Seoul National Univ.) |
10:36~10:47 |
Outbreak of Pneumocystis Pneumonia in Long-Term Renal Transplant Recipients |
Atsushi Aikawa(Toho Univ.) |
10:48~10:59 |
A case of everolimus-associated chylothorax in a cardiac transplant recipient |
Norihide Fukushima(Osaka Univ.) |
11:00~12:20 |
Free paper 4 : Kidney Moderator : Kenji Yuzawa (National Hospital Organization Mito Medical Center), Ik Jin Yun(Konkuk Univ.) |
11:00~11:11 |
Late-onset neutropenia after low-dose rituximab treatment. |
Mr Hideki ISHIDA(TWMU) |
11:11~11:22 |
Successful Withdrawal of Antiviral Therapy in Kidney Transplants with Chronic
Hepatitis B infection |
Jang Hee Cho(Kyungpook National Univ.) |
11:22~11:33 |
Banff Working Proposal for Polyomavirus BK nephropathy |
Kosuke Masutani(Kyushu Univ.) |
11:34~11:45 |
High Pre-transplant Hepatitis B Virus (HBV) Level Predicts HBV Reactivation after
Kidney Transplantation in HBV Infected Recipients |
Jong Man Kim(Sungkyunkwan Univ.) |
11:45~11:56 |
The Fate of 527 Renal Allografts Retrieved from Donors after Cardiac Death (Fujita
Experience) |
Mamoru Kusaka(Fujita-Health Univ.) |
11:56~12:07 |
The influences of pregnancy on renal function of women with allograft kidney in
peripartum period |
Hyosang Kim(Ulsan Univ.) |
11:08~11:19 |
Outcomes of Retroperitoneoscopic Procurement of Kidneys with Multiple Renal
Arteries. |
Kazuya Omoto(Tokyo Women's Medical Univ.) |
11:00~12:20 |
Free paper 5 : Liver Moderator : Hiroaki Nagano (Osaka Univ.), Jae Won Joh (Sungkyunkwan Univ.) |
11:00~11:11 |
Role of hand-assisted laparoscopic surgery (HALS) for living donor right lobe harvest |
Tae-Yong Ha(Ulsan Univ.) |
11:11~11:22 |
A hybrid procedure of laparoscopic-assisted open liver resection in living donor
Hetapectomy |
MItsuhisa Takatsuki(Nagasaki Univ.) |
11:22~11:33 |
Does procurement technique affect posttransplant graft function in DDLT? |
Sung Won Jung(Korea Univ.) |
11:34~11:45 |
An experience of hemitransposition for a patient with a massive thrombus of the
portal trunk and SMV |
Ryuji Sakuyama(Tokyo Womens' Medical Univ.) |
11:45~11:56 |
The choice of the right or left hepatic artery in right lobe living donor liver
Transplantation |
Young Seok Han(Daegu Catholic univ.) |
11:56~12:07 |
Living donor liver transplantation with alternative porto-left gastric vein anastomosis
in patients with post-Kasai extrahepatic portal vein obstruction |
Toshihiro Kitajima(National Center for Child Health and Development) |
11:08~11:19 |
Graft function measured by transient elastography in living donor liver transplantation |
Su Hyung Lee(Yonsei Univ.) |
11:00~12:20 |
Free paper 6 : Basic and Other Moderator : Tetsuya Kiuchi(Nagoya Univ.), Curie Ahn (Seoul Univ.) |
11:00~11:11 |
Mycophenolic acid regulates Sky to repress TNF¥á-induced MCP-1 production in
aortic endothelial cell |
Tai Yeon Koo(Seoul National Univ.) |
11:11~11:22 |
Inhalation of hydrogen reduced ischemia/reperfusion lung injury through heme
oxygenase-1 induction |
Tomohiro Kawamura(Osaka Univ.) |
11:22~11:33 |
Current outcome of deceased donor pancreas/pancreas-kidney transplantation in
Japan |
Taihei Ito(Fujita-Health Univ.) |
11:34~11:45 |
Japanese strategies for maximizing lung availabilities: Experience from 100
consecutive donation |
Norihide Fukushima(Osaka Univ.) |
11:45~11:56 |
Analysis of the processing time from the brain death to transplantation for the face
Transplantation |
Jong won HONG(Yonesei Univ.) |
11:56~12:07 |
A case of strongly suspected acute GVHD following simultaneous pancreas-kidney
Transplant |
Sadaki Asari(Kobe Univ.) |
11:08~11:19 |
Graft-versus-Host Disease (GVHD) following cadaveric kidney transplantation |
Yuhji MARUI(Toranomon Hospital Kajigaya) |
12:30~13:30 |
Lunchen Symposium III (Novartis) - Certican |
13:30~14:30 |
ÇØ¿Ü¿¬¼öÀåÇÐ±Ý º¸°í
ÁÂÀå : ¹Ú¼º±¤ (ÀüºÏÀÇ´ë)/±è¼®¿µ (°¡Å縯ÀÇ´ë) |
13:30~13:45 |
The Living Donor Evaluation as a Life-Saving Event |
¹Ú¼øö(°¡Å縯ÀÇ´ë) |
13:45~14:00 |
Viral metagenomics in transplantation |
±è¿µ¼ö(°¡Å縯ÀÇ´ë) |
14:00~14:15 |
Clinical experience in intestinal transplantation |
¾ÈÇüÁØ(°æÈñÀÇ´ë) |
14:15~14:30 |
Natural IgM Anti-Leukocyte Autoantibodies(IgM-ALA) Block Immune Mediated
Pro-inflammatory Cytokine Release through Inhibition of NF-kB Activation
|
ÀÌ»óÁÖ(°¡Å縯ÀÇ´ë) |
13:30~14:30 |
ÀÚÀ¯¿¬Á¦ 7 : Basic and Liver ÁÂÀå : ±è¼ºÁÖ (¼º±Õ°üÀÇ´ë) ¹ÚÁ¤±Ô (¼¿ïÀÇ´ë) |
13:30~13:42 |
Drug interaction between TAC and EVR in chronic TAC-induced nephrotoxicity and
pancreatic injury |
Shang Guo Piao(°¡Å縯ÀÇ´ë) |
13:42~13:54 |
Prognostic value of pretransplant peripheral blood monocyte count in patients
undergoing liver transplantation for hepatocellular carcinoma |
±è¿µ±Ô(±¹¸³¾Ï¼¾ÅÍ) |
13:54~14:06 |
Do Donor Specific Antibodies Affect Graft Liver Outcomes in LDLT? |
ÁÖµ¿Áø(¿¬¼¼ÀÇ´ë) |
14:06~14:18 |
Significant Donor Hyporesponsiveness in Pediatric Patients Over 3 years After LTLD |
°Àº¼÷(¼¿ïÀÇ´ë) |
14:18~14:30 |
Perioperative AFP Levels: Useful Markers Predicting Prognosis of Hepatocellular
carcinoma Patients |
À¯Å¼®(¼¿ïÀÇ´ë) |
14:30~14:45 |
Coffee Break |
14:45~16:00 |
ÀÚÀ¯¿¬Á¦ 8 : Kidney ÁÂÀå : ±èÁß°æ (ºÀ»ýº´¿ø) Á¶È«·¡ (¿ï»êÀÇ´ë) |
14:45~14:57 |
Comparison between CKD-EPI and MDRD equation in the estimation of renal
function in kidney donors |
Á¤º´ÇÏ(°¡Å縯ÀÇ´ë) |
14:57~15:09 |
Infectious complications associated with desensitization in kidney transplant
Recipients |
À̸íÇö(°¡Å縯ÀÇ´ë) |
15:10~15:22 |
Risk factors for recurrent urinary tract infection in kidney transplant recipients |
ÀÓÁ¤ÈÆ(°æºÏÀÇ´ë) |
15:22~15:34 |
Monitoring and Treatment of BK virus infection in Kidney Transplantation |
¹®Çüȯ(¼º±Õ°üÀÇ´ë) |
15:35~15:47 |
The clinical courses of renal transplant recipients with high BK viremia |
±èÈ¿»ó(¿ï»êÀÇ´ë) |
15:47~15:59 |
Impact of Combined Acute Rejection on BK Virus-Associated Nephropathy in kidney
Transplantation |
±èÀ±Á¤(¼¿ïÀÇ´ë) |
14:45~16:00 |
ÀÚÀ¯¿¬Á¦ 9 : Liver ÁÂÀå : ±èÁÖ¼· (ÇѸ²ÀÇ´ë) ÃÖÁ¾¿µ (°¡Å縯ÀÇ´ë) |
14:45~14:57 |
Outcomes of liver transplantation for combined hepatocellular carcinoma and
Cholangiocarcinoma |
¹Ú¿äÇÑ(¿ï»êÀÇ´ë) |
14:57~15:09 |
LDLT after neoadjuvant concurrent chemoradiation therapy combined with
multimodal treatment for HCC |
ÇÑ´ëÈÆ(¿¬¼¼ÀÇ´ë) |
15:10~15:22 |
The outcome of liver transplantation for combined hepatocellular-
cholangiocarcinoma patient |
¼Û»óÇö(¼º±Õ°üÀÇ´ë) |
15:22~15:34 |
Small for size living donor graft showed higher incidence of hepatocellular
carcinoma recurrence |
¹Ú¹Î¼ö(¼¿ïÀÇ´ë) |
15:35~15:47 |
Liver Transplantation in Lymphoma Patients with Hepatitis B Virus Reactivation |
±èÁ¾¸¸(¼º±Õ°üÀÇ´ë) |
15:47~15:59 |
Transarterial radioembolization (TARE) using Yttrium-90 microspheres for advanced Hepatocellular carcinoma prior to living donor liver transplantation : our experience of 3 cases |
À¯¿µµ¿(°í·ÁÀÇ´ë) |
14:45~16:00 |
ÀÚÀ¯¿¬Á¦ 10 : Coordinator ÁÂÀå : ±è¸íÈñ (¿µ³²´ëÇб³º´¿ø) Àü°æ¿Á (¼¼ºê¶õ½ºº´¿ø) |
14:45~15:03 |
°£À̽ÄȯÀÚÀÇ Áõ»ó°íÅë°¨, »çȸÀûÁöÁö, »îÀÇ Áú¿¡ °üÇÑ ¿¬±¸ |
Àü°æ¿Á(¼¼ºê¶õ½ºº´¿ø) |
15:04~15:22 |
Change in donor quality of life after living donor kidney transplantation surgery |
±èº¹³à(»ï¼º¼¿ïº´¿ø) |
15:23~15:41 |
°£ÀÌ½Ä È¯ÀÚÀÇ ¸é¿ª¾ïÁ¦Á¦ º¹¿ëÀÌÇà ½ÇÅ |
À̼±¿µ(¼¼ºê¶õ½ºº´¿ø) |
15:42~16:00 |
¼¿ï¾Æ»êº´¿ø ÇìÆĺò(Hepatitis B Immunoglobulin) ÁÖ»çÇöȲ ¹× ÁÖ»ç¹æ¹ý °íÂû |
ÇÏÈñ¼±(¼¿ï¾Æ»êº´¿ø) |
16:00~16:15 |
Coffee Break |
16:15~17:30 |
ÀÚÀ¯¿¬Á¦ 11 : Kidney ÁÂÀå : ±è¿ë¸² (°æºÏÀÇ´ë) ¿Àâ±Ç (¾ÆÁÖÀÇ´ë) |
16:15~16:27 |
The Intermediate-Term outcomes of Renal Transplantation with Expanded Criteria
Deceased Donors |
±èÁöÀÏ(°¡Å縯ÀÇ´ë) |
16:27~16:39 |
Outcomes of expanded criteria-deceased donor kidney transplantation in a single
Korean center |
Çѹ̿¬(¼¿ïÀÇ´ë) |
16:40~16:52 |
The initial results of the DDKT from the new kidney transplantation center |
¹®ÁÖÀÍ(°Ç¾çÀÇ´ë) |
16:52~17:04 |
Risk factors and clinical outcomes for delayed graft function with deceased donor
renal transplant |
±èÁöÀÏ(°¡Å縯ÀÇ´ë) |
16:05~16:17 |
Hand-Assisted Laparoscopic Donor Nephrectomy Using Low Transverse Incision for
the Hand-Assist Port : comaparative outcome of hand-assisted laparoscopic donor
nephrecotmy using midline incision and low transverse incision (Video Presentation) |
Á¤Ã¶¿õ(°í·ÁÀÇ´ë) |
16:17~16:29 |
Can shear wave velocity of donor kidney predict graft function after transplantation? |
À̾ƶõ(¿¬¼¼ÀÇ´ë) |
16:15~17:30 |
ÀÚÀ¯¿¬Á¦ 12 : Liver ÁÂÀå : À¯¿µ°æ (°¡Å縯ÀÇ´ë) °±¸Á¤ (°è¸íÀÇ´ë) |
16:15~16:27 |
Middle hepatic vein reconstruction by using Dacron graft in right lobe living donor
liver transplantation |
ÇÑ¿µ¼®(´ë±¸°¡Å縯ÀÇ´ë) |
16:27~16:39 |
Left hepatic vein anatomy and venoplasty techniques for pediatric living donor liver
Transplantation |
Ȳ½Å(¿ï»êÀÇ´ë) |
16:40~16:52 |
Small for size living donor graft showed higher incidence of hepatocellular
carcinoma recurrence |
¹Ú¹Î¼ö(¼¿ïÀÇ´ë) |
16:52~17:04 |
Single center experience of liver transplantation in patients with portal vein
Thrombosis |
¼Û»óÇö(¼º±Õ°üÀÇ´ë) |
16:05~16:17 |
LDLT after Inferior Vena Cava Replacement using Artificial Vascular Graft in Cirrhotic
and Advanced Hepatocellular carcinoma (Video presentation) |
¹®´öº¹(¿ï»êÀÇ´ë) |
16:17~16:29 |
Salvage dual LDLT for HCC after major hepatectomy |
±èÁÖµ¿(´ë±¸°¡Å縯ÀÇ´ë) |
16:15~17:30 |
Coordinator Symposium
ÁÂÀå: º¹ÃáÈñ(Çѱ¹Àå±â±âÁõ¿ø)/È«Á¤ÀÚ(¼¿ï¾Æ»êº´¿ø) |
16:15~16:40 |
Àå±âÀÌ½Ä ÈÄ °¨¿° °ü¸® |
¹ÚÀº¼÷(¼¼ºê¶õ½ºº´¿ø) |
16:40~17:05 |
ÃéÀå À̽İú Ãéµµ ÀÌ½Ä |
¹ÚÀç¹ü(¼º±Õ°üÀÇ´ë) |
17:05~17:30 |
ÃÑȸ |
17:30~18:00 |
Awards Ceremony |
18:00~ |
Æóȸ |